{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:09:15Z","timestamp":1789153755752,"version":"build-2803163510"},"reference-count":149,"publisher":"Society of Nuclear Medicine","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.125.269487","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:16Z","timestamp":1789152016000},"page":"5S-16S","source":"Crossref","is-referenced-by-count":0,"title":["Expanding the Theranostic Toolbox: Emerging Therapeutic Isotopes"],"prefix":"10.2967","volume":"67","author":[{"given":"Cindy","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Liles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091111400909000_67.Supplement_2.5S.1","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a Lancet Oncology commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026091111400909000_67.Supplement_2.5S.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00652-y"},{"key":"2026091111400909000_67.Supplement_2.5S.3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11912-025-01686-y","article-title":"Prostate cancer radioligand therapy: PSMA and beyond, current landscape and future directions","volume":"27","author":"Bent","year":"2025","journal-title":"Curr Oncol Rep."},{"key":"2026091111400909000_67.Supplement_2.5S.4","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","article-title":"Production and regulatory issues for theranostics","volume":"25","author":"Giammarile","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026091111400909000_67.Supplement_2.5S.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265976"},{"key":"2026091111400909000_67.Supplement_2.5S.6","doi-asserted-by":"crossref","first-page":"112138","DOI":"10.1016\/j.apradiso.2025.112138","article-title":"Separation of terbium from proton-irradiated gadolinium oxide targets: development of an effective, scalable and automatable process","volume":"226","author":"Peikin","year":"2025","journal-title":"Appl Radiat Isot."},{"key":"2026091111400909000_67.Supplement_2.5S.7","doi-asserted-by":"crossref","first-page":"13705","DOI":"10.1021\/acs.jmedchem.3c01151","article-title":"Rearmed bifunctional chelating ligand for 225Ac\/155Tb precision-guided theranostic radiopharmaceuticals\u2014H4noneunpaX","volume":"66","author":"Wharton","year":"2023","journal-title":"J Med Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.8","doi-asserted-by":"crossref","unstructured":"Palihati M Das JP Yeh R Capaccione K . Emerging PET imaging agents and targeted radioligand therapy: a review of clinical applications and trials. Tomography. 2025;11:83.","DOI":"10.3390\/tomography11080083"},{"key":"2026091111400909000_67.Supplement_2.5S.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261016"},{"key":"2026091111400909000_67.Supplement_2.5S.10","doi-asserted-by":"crossref","first-page":"109027","DOI":"10.1016\/j.nucmedbio.2025.109027","article-title":"Potent candidates for targeted alpha therapy (TAT)","volume":"146\u2013147","author":"Filosofov","year":"2025","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00030-5"},{"key":"2026091111400909000_67.Supplement_2.5S.12","doi-asserted-by":"crossref","first-page":"109535","DOI":"10.1016\/j.apradiso.2020.109535","article-title":"Estimation and verification of 131I yield from fission and irradiation of tellurium","volume":"168","author":"Mishra","year":"2021","journal-title":"Appl Radiat Isot."},{"key":"2026091111400909000_67.Supplement_2.5S.13","unstructured":"Dhingra J Halkar R . I-131 MIBG therapy has been used as the first line therapy in pheochromocytoma [abstract]. J Nucl Med. 2020:61(suppl 1):1451."},{"key":"2026091111400909000_67.Supplement_2.5S.14","doi-asserted-by":"crossref","unstructured":"Ladriere T Faudemer J Levigoureux E Peyronnet D Desmonts C Vigne J . Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals. Pharmaceutics. 2023;15:1240.","DOI":"10.3390\/pharmaceutics15041240"},{"key":"2026091111400909000_67.Supplement_2.5S.15","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-014-0315-z"},{"key":"2026091111400909000_67.Supplement_2.5S.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2011.05.004"},{"key":"2026091111400909000_67.Supplement_2.5S.17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jlcr.3140","article-title":"A systematic comparative evaluation of 90Y-labeled bifunctional chelators for their use in targeted therapy","volume":"57","author":"Chakravarty","year":"2014","journal-title":"J Labelled Comp Radiopharm."},{"key":"2026091111400909000_67.Supplement_2.5S.18","doi-asserted-by":"crossref","unstructured":"Tavarozzi R Zacchi G Pietrasanta D . Changing trends in B-cell non-Hodgkin lymphoma treatment: the role of novel monoclonal antibodies in clinical practice. Cancers (Basel). 2023;15:5397.","DOI":"10.3390\/cancers15225397"},{"key":"2026091111400909000_67.Supplement_2.5S.19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.37349\/etat.2024.00213","article-title":"Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin\u2019s lymphoma","volume":"5","author":"Goto","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"key":"2026091111400909000_67.Supplement_2.5S.20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.adro.2016.08.003","article-title":"The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres","volume":"1","author":"Westcott","year":"2016","journal-title":"Adv Radiat Oncol."},{"key":"2026091111400909000_67.Supplement_2.5S.21","first-page":"621","article-title":"Availability of yttrium-90 from strontium-90: a nuclear medicine perspective","volume":"27","author":"Chakravarty","year":"2012","journal-title":"Cancer Biother Radiopharm."},{"key":"2026091111400909000_67.Supplement_2.5S.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2007.10.009"},{"key":"2026091111400909000_67.Supplement_2.5S.23","doi-asserted-by":"crossref","unstructured":"Krasnovskaya OO Abramchuck D Erofeev A . Recent advances in 64Cu\/67Cu-based radiopharmaceuticals. Int J Mol Sci. 2023;24:9154.","DOI":"10.3390\/ijms24119154"},{"key":"2026091111400909000_67.Supplement_2.5S.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.180430"},{"key":"2026091111400909000_67.Supplement_2.5S.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266171"},{"key":"2026091111400909000_67.Supplement_2.5S.26","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1021\/acs.molpharmaceut.0c00060","article-title":"Preclinical evaluation of a high-affinity sarcophagine-containing PSMA ligand for 64Cu\/67Cu-based theranostics in prostate cancer","volume":"17","author":"Kelly","year":"2020","journal-title":"Mol Pharm."},{"key":"2026091111400909000_67.Supplement_2.5S.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251579"},{"key":"2026091111400909000_67.Supplement_2.5S.28","doi-asserted-by":"crossref","unstructured":"Huynh TT van Dam EM Sreekumar S . Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer. Pharmaceuticals (Basel). 2022;15:728.","DOI":"10.3390\/ph15060728"},{"key":"2026091111400909000_67.Supplement_2.5S.29","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/acsabm.0c01555","article-title":"Successful application of CuAAC click reaction in constructing 64Cu-labeled antibody conjugates for immuno-PET imaging","volume":"4","author":"Lee","year":"2021","journal-title":"ACS Appl Bio Mater."},{"key":"2026091111400909000_67.Supplement_2.5S.30","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1038\/s41598-021-82812-1","article-title":"Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT","volume":"11","author":"Hao","year":"2021","journal-title":"Sci Rep."},{"key":"2026091111400909000_67.Supplement_2.5S.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009960117"},{"key":"2026091111400909000_67.Supplement_2.5S.32","unstructured":"Copper 64Cu-DOTA-daratumumab positron emission tomography in diagnosing patients with relapsed multiple myeloma. Clinicaltrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT03311828. Updated March 12, 2024. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.33","unstructured":"An investigational scan (64Cu-labeled M5A antibody) in combination with SOC chemotherapy and radiotherapy in locally advanced rectal cancer. Clinicaltrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT05245786. Updated November 7, 2025. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.34","unstructured":"An investigational scan (64Cu-DOTA-trastuzumab PET\/MRI) in imaging patients with HER2+ breast cancer with brain metastasis. Clinicaltrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT05376878. Updated February 18, 2025. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.35","unstructured":"Cu-64-PSMA-I&T positron emission tomography (PET) imaging of metastatic PSMA positive lesions in men with prostate cancer. Clinicaltrials.gov website. https:\/\/www.clinicaltrials.gov\/study\/NCT05653856. Updated January 24, 2025. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.36","unstructured":"64Cu-ATSM PET\/CT in rectum cancer (TEP 64Cu-ATSM-rectum). Clinicaltrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT03951337. Updated March 12, 2024. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.37","unstructured":"67Cu-SARTATE\u2122 peptide receptor radionuclide therapy administered to pediatric patients with high-risk, relapsed, refractory neuroblastoma. Clinicaltrials.gov website. https:\/\/www.clinicaltrials.gov\/study\/NCT04023331. Updated September 16, 2025. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.38","unstructured":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE). Clinicaltrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT04868604. Updated June 19, 2025. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264586"},{"key":"2026091111400909000_67.Supplement_2.5S.40","doi-asserted-by":"crossref","unstructured":"Mou L Martini P Pupillo G Cieszykowska I Cutler CS Miko\u0142ajczak R . 67Cu production capabilities: a mini review. Molecules. 2022;27:1501.","DOI":"10.3390\/molecules27051501"},{"key":"2026091111400909000_67.Supplement_2.5S.41","doi-asserted-by":"crossref","unstructured":"Siwowska K Guzik P Domnanich KA . Therapeutic potential of 47Sc in comparison to 177Lu and 90Y: preclinical investigations. Pharmaceutics. 2019:11:424.","DOI":"10.3390\/pharmaceutics11080424"},{"key":"2026091111400909000_67.Supplement_2.5S.42","first-page":"P1455","article-title":"Preclinical study of a novel radiotheranostic pair for neuroendocrine tumors: 43Sc\/47Sc-DOTATATE [abstract]","volume":"64(suppl 1)","author":"Pusateri","year":"2023","journal-title":"J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.43","doi-asserted-by":"crossref","unstructured":"Su D Liao Y Wang J . Synthesis and preliminary evaluation of 47Sc-labeled FAPI-46 for cancer theranostics. J Radioanal Nucl Chem. 2025;334:5691\u20135699.","DOI":"10.1007\/s10967-025-10281-1"},{"key":"2026091111400909000_67.Supplement_2.5S.44","first-page":"P678","article-title":"Exploring the theranostic potential of 43Sc-PSMA-617 and 47Sc-PSMA-617 [abstract]","volume":"64(suppl 1)","author":"Cingoranelli","year":"2023","journal-title":"J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.45","first-page":"2895","article-title":"Development of 43Sc\/47Sc-PSMA-617 as theranostics for prostate cancer: preliminary cellular and animal studies [abstract]","volume":"63(suppl 2)","author":"Meier","year":"2022","journal-title":"J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-021-00131-2","article-title":"Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements","volume":"6","author":"Mikolajczak","year":"2021","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.47","doi-asserted-by":"crossref","first-page":"22683","DOI":"10.1038\/s41598-023-49377-7","article-title":"Production and purification of 43Sc and 47Sc from enriched [46Ti]TiO2 and [50Ti]TiO2 targets","volume":"13","author":"Cingoranelli","year":"2023","journal-title":"Sci Rep."},{"key":"2026091111400909000_67.Supplement_2.5S.48","doi-asserted-by":"crossref","first-page":"109934","DOI":"10.1016\/j.apradiso.2021.109934","article-title":"High purity 47Sc production using high-energy photons and natural vanadium targets","volume":"178","author":"Snow","year":"2021","journal-title":"Appl Radiat Isot."},{"key":"2026091111400909000_67.Supplement_2.5S.49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s41181-024-00321-8","article-title":"Production of high purity 47Sc from proton irradiation of natural vanadium targets","volume":"9","author":"Cingoranelli","year":"2024","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267611"},{"key":"2026091111400909000_67.Supplement_2.5S.51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/RLU.0000000000004589","article-title":"New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC","volume":"48","author":"Rosar","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.52","doi-asserted-by":"crossref","first-page":"1472500","DOI":"10.3389\/fnume.2024.1472500","article-title":"Terbium sisters: current development status and upscaling opportunities","volume":"4","author":"Moiseeva","year":"2024","journal-title":"Front Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.53","doi-asserted-by":"crossref","first-page":"110840","DOI":"10.1016\/j.apradiso.2023.110840","article-title":"Photonuclear production of medical radioisotopes 161Tb and 155Tb","volume":"198","author":"Fedotova","year":"2023","journal-title":"Appl Radiat Isot."},{"key":"2026091111400909000_67.Supplement_2.5S.54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0298"},{"key":"2026091111400909000_67.Supplement_2.5S.55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","article-title":"An overview of targeted alpha therapy","volume":"33","author":"Kim","year":"2012","journal-title":"Tumour Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.56","first-page":"475","article-title":"Targeted alpha-therapy in cancer management: synopsis of preclinical and clinical studies","volume":"35","author":"Jadvar","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"2026091111400909000_67.Supplement_2.5S.57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw065"},{"key":"2026091111400909000_67.Supplement_2.5S.58","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2016.06.002","article-title":"Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial","volume":"70","author":"Parker","year":"2016","journal-title":"Eur Urol."},{"key":"2026091111400909000_67.Supplement_2.5S.59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.10.020","article-title":"Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial","volume":"71","author":"Parker","year":"2017","journal-title":"Eur J Cancer."},{"key":"2026091111400909000_67.Supplement_2.5S.60","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/pros.23180","article-title":"Chemotherapy following radium-223 dichloride treatment in ALSYMPCA","volume":"76","author":"Sartor","year":"2016","journal-title":"Prostate."},{"key":"2026091111400909000_67.Supplement_2.5S.61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clgc.2016.07.027","article-title":"Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial","volume":"15","author":"Vogelzang","year":"2017","journal-title":"Clin Genitourin Cancer."},{"key":"2026091111400909000_67.Supplement_2.5S.62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70474-7"},{"key":"2026091111400909000_67.Supplement_2.5S.63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.007","article-title":"Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation\/randomised phase 2a trial","volume":"114","author":"Morris","year":"2019","journal-title":"Eur J Cancer."},{"key":"2026091111400909000_67.Supplement_2.5S.64","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s00259-018-4234-6","article-title":"Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study","volume":"46","author":"Geva","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400909000_67.Supplement_2.5S.65","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00259-019-4261-y","article-title":"Interim analysis of the REASSURE (radium-223 alpha emitter agent in non-intervention safety study in mCRPC population for long-term evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice","volume":"46","author":"Dizdarevic","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400909000_67.Supplement_2.5S.66","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2939-1"},{"key":"2026091111400909000_67.Supplement_2.5S.67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3964"},{"key":"2026091111400909000_67.Supplement_2.5S.68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/1874471011666180525102814","article-title":"Clinical studies with bismuth-213 and actinium-225 for hematologic malignancies","volume":"11","author":"Jurcic","year":"2018","journal-title":"Curr Radiopharm."},{"key":"2026091111400909000_67.Supplement_2.5S.69","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2026091111400909000_67.Supplement_2.5S.70","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"2026091111400909000_67.Supplement_2.5S.71","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12885-024-11900-y","article-title":"Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study","volume":"24","author":"Ling","year":"2024","journal-title":"BMC Cancer."},{"key":"2026091111400909000_67.Supplement_2.5S.72","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00259-021-05350-y","article-title":"Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma: safety and efficacy","volume":"48","author":"Krolicki","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400909000_67.Supplement_2.5S.73","doi-asserted-by":"crossref","first-page":"e233408","DOI":"10.1148\/radiol.233408","article-title":"Dotatate PET\/CT and 225Ac-Dotatate therapy for somatostatin receptor-expressing metastatic breast cancer","volume":"312","author":"Ulaner","year":"2024","journal-title":"Radiology."},{"key":"2026091111400909000_67.Supplement_2.5S.74","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","article-title":"Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator actinium-225-lintuzumab","volume":"28","author":"Rosenblat","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026091111400909000_67.Supplement_2.5S.75","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.6.6.4089","article-title":"Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma","volume":"6","author":"Raja","year":"2007","journal-title":"Cancer Biol Ther."},{"key":"2026091111400909000_67.Supplement_2.5S.76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0382"},{"key":"2026091111400909000_67.Supplement_2.5S.77","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood."},{"key":"2026091111400909000_67.Supplement_2.5S.78","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tranon.2017.04.004","article-title":"Targeted alpha-particle radiation therapy of HER1-positive disseminated intraperitoneal disease: an investigation of the human anti-EGFR monoclonal antibody, panitumumab","volume":"10","author":"Milenic","year":"2017","journal-title":"Transl Oncol."},{"key":"2026091111400909000_67.Supplement_2.5S.79","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-018-4015-2","article-title":"Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue","volume":"45","author":"Krolicki","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400909000_67.Supplement_2.5S.80","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1385-5"},{"key":"2026091111400909000_67.Supplement_2.5S.81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2820"},{"key":"2026091111400909000_67.Supplement_2.5S.82","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3657-9"},{"key":"2026091111400909000_67.Supplement_2.5S.83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1874471011104040283","article-title":"Applications of 211At and 223Ra in targeted alpha-particle radiotherapy","volume":"4","author":"Vaidyanathan","year":"2011","journal-title":"Curr Radiopharm."},{"key":"2026091111400909000_67.Supplement_2.5S.84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nucmedbio.2021.05.007","article-title":"Production, purification and availability of 211At: near term steps towards global access","volume":"100\u2013101","author":"Feng","year":"2021","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.85","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.062604"},{"key":"2026091111400909000_67.Supplement_2.5S.86","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.046938"},{"key":"2026091111400909000_67.Supplement_2.5S.87","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2013.1531"},{"key":"2026091111400909000_67.Supplement_2.5S.88","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000353"},{"key":"2026091111400909000_67.Supplement_2.5S.89","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.143842"},{"key":"2026091111400909000_67.Supplement_2.5S.90","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","article-title":"Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy?","volume":"46","author":"Dos Santos","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400909000_67.Supplement_2.5S.91","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269299"},{"key":"2026091111400909000_67.Supplement_2.5S.92","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263230"},{"key":"2026091111400909000_67.Supplement_2.5S.93","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267189"},{"key":"2026091111400909000_67.Supplement_2.5S.94","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-023-06529-1","article-title":"First-in-human SPECT\/CT imaging of [212Pb]Pb-VMT-alpha-NET in a patient with metastatic neuroendocrine tumor","volume":"51","author":"Michler","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400909000_67.Supplement_2.5S.95","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/cancers16101799","article-title":"CXCR4: from signaling to clinical applications in neuroendocrine neoplasms","volume":"16","author":"Sanchis-Pascual","year":"2024","journal-title":"Cancers (Basel)."},{"key":"2026091111400909000_67.Supplement_2.5S.96","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186338"},{"key":"2026091111400909000_67.Supplement_2.5S.97","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.204651"},{"key":"2026091111400909000_67.Supplement_2.5S.98","first-page":"672","article-title":"227Th-labeled anti-CD22 antibody (BAY 1862864) in relapsed\/refractory CD22-positive non-Hodgkin lymphoma: a first-in-human, phase I study","volume":"36","author":"Linden","year":"2021","journal-title":"Cancer Biother Radiopharm."},{"key":"2026091111400909000_67.Supplement_2.5S.99","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.7150\/thno.92775","article-title":"Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside","volume":"14","author":"Van Laere","year":"2024","journal-title":"Theranostics."},{"key":"2026091111400909000_67.Supplement_2.5S.100","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41598-024-53610-2","article-title":"Terbium-149 production: a focus on yield and quality improvement towards preclinical application","volume":"14","author":"Favaretto","year":"2024","journal-title":"Sci Rep."},{"key":"2026091111400909000_67.Supplement_2.5S.101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejmp.2018.05.020","article-title":"Targeted alpha therapy with 212Pb or 225Ac: change in RBE from daughter migration","volume":"51","author":"Ackerman","year":"2018","journal-title":"Phys Med."},{"key":"2026091111400909000_67.Supplement_2.5S.102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics."},{"key":"2026091111400909000_67.Supplement_2.5S.103","doi-asserted-by":"crossref","first-page":"15749","DOI":"10.1038\/s41598-021-94922-x","article-title":"Heavy-ion production of 77Br and 76Br","volume":"11","author":"McGuinness","year":"2021","journal-title":"Sci Rep."},{"key":"2026091111400909000_67.Supplement_2.5S.104","doi-asserted-by":"crossref","first-page":"108368","DOI":"10.1016\/j.nucmedbio.2023.108368","article-title":"Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer","volume":"122\u2013123","author":"Hoffman","year":"2023","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.105","doi-asserted-by":"crossref","unstructured":"Sreekumar S Zhou D Mpoy C . Preclinical efficacy of a PARP-1 targeted Auger-emitting radionuclide in prostate cancer. Int J Mol Sci. 2023;24:3083.","DOI":"10.3390\/ijms24043083"},{"key":"2026091111400909000_67.Supplement_2.5S.106","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.09.001","article-title":"Improved production of 76Br, 77Br and 80mBr via CoSe cyclotron targets and vertical dry distillation","volume":"80\u201381","author":"Ellison","year":"2020","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.717180"},{"key":"2026091111400909000_67.Supplement_2.5S.108","doi-asserted-by":"crossref","first-page":"1533033819825845","DOI":"10.1177\/1533033819825845","article-title":"Permanent iodine-125 seed implantation for the treatment of nonresectable retroperitoneal malignant tumors","volume":"18","author":"Li","year":"2019","journal-title":"Technol Cancer Res Treat."},{"key":"2026091111400909000_67.Supplement_2.5S.109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.lungcan.2007.12.016","article-title":"CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC)","volume":"61","author":"Martinez-Monge","year":"2008","journal-title":"Lung Cancer."},{"key":"2026091111400909000_67.Supplement_2.5S.110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1748-717X-6-138","article-title":"Clinical application of CT-guided 125I seed interstitial implantation for local recurrent rectal carcinoma","volume":"6","author":"Wang","year":"2011","journal-title":"Radiat Oncol."},{"key":"2026091111400909000_67.Supplement_2.5S.111","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-009-1703-0"},{"key":"2026091111400909000_67.Supplement_2.5S.112","doi-asserted-by":"crossref","first-page":"8575","DOI":"10.1021\/ie301063h","article-title":"Production of I from neutron irradiation of natural Xe gas and a wet distillation process for radiopharmaceutical applications","volume":"51","author":"Joshi","year":"2012","journal-title":"Ind Eng Chem Res."},{"key":"2026091111400909000_67.Supplement_2.5S.113","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265429"},{"key":"2026091111400909000_67.Supplement_2.5S.114","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/09553002.2020.1781283","article-title":"Improved radiosynthesis of 123I-MAPi, an Auger theranostic agent","volume":"99","author":"Wilson","year":"2023","journal-title":"Int J Radiat Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2440"},{"key":"2026091111400909000_67.Supplement_2.5S.116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijnm.ijnm_104_24","article-title":"A perspective on production and quality control of iodine-123 radiopharmaceutical for applications in nuclear medicine","volume":"40","author":"Lego","year":"2025","journal-title":"Indian J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.117","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0883-2889(89)90187-1","article-title":"Excitation functions of proton induced nuclear reactions on natural tellurium and enriched 123Te: production of 123I via the 123Te (p,n)123I-process at a low-energy cyclotron","volume":"40","author":"Scholten","year":"1989","journal-title":"Int J Appl Radiat Isot."},{"key":"2026091111400909000_67.Supplement_2.5S.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2021.03.002"},{"key":"2026091111400909000_67.Supplement_2.5S.119","unstructured":"TGW211 for click-cleavable imaging in HER2-positive cancers (CleavHER). ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT07009184. Updated November 18, 2025. Accessed November 21, 2025."},{"key":"2026091111400909000_67.Supplement_2.5S.120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41181-018-0038-z","article-title":"Production of novel diagnostic radionuclides in small medical cyclotrons","volume":"3","author":"Synowiecki","year":"2018","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.121","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nucmedbio.2016.10.008","article-title":"Re-assessing gallium-67 as a therapeutic radionuclide","volume":"46","author":"Othman","year":"2017","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.122","first-page":"86","article-title":"Safety and tolerability of Miltuximab\u00ae: a first in human study in patients with advanced solid cancers","volume":"9","author":"Sabanathan","year":"2021","journal-title":"Asia Ocean J Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.123","first-page":"1","article-title":"RetroSPECT: gallium-67 as a long-lived imaging agent for theranostics","volume":"9","author":"Bailey","year":"2021","journal-title":"Asia Ocean J Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.124","first-page":"P677","article-title":"Production and purification of high specific activity lead-203 (203Pb) for preclinical applications [abstract]","volume":"64(suppl 1)","author":"Shefali","year":"2023","journal-title":"J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.125","doi-asserted-by":"crossref","first-page":"10623","DOI":"10.1038\/s41598-023-37313-8","article-title":"Optimized production, purification, and radiolabeling of the 203Pb\/212Pb theranostic pair for nuclear medicine","volume":"13","author":"McNeil","year":"2023","journal-title":"Sci Rep."},{"key":"2026091111400909000_67.Supplement_2.5S.126","doi-asserted-by":"crossref","first-page":"108314","DOI":"10.1016\/j.nucmedbio.2023.108314","article-title":"High-yield cyclotron production of 203Pb using a sealed 205Tl solid target","volume":"116\u2013117","author":"Nelson","year":"2023","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.127","doi-asserted-by":"crossref","unstructured":"Obata H Tsuji AB Sudo H . Novel Auger-electron-emitting 191Pt-labeled pyrrole-imidazole polyamide targeting MYCN increases cytotoxicity and cytosolic dsDNA granules in MYCN-amplified neuroblastoma. Pharmaceuticals (Basel). 2023;16:1526.","DOI":"10.3390\/ph16111526"},{"key":"2026091111400909000_67.Supplement_2.5S.128","first-page":"P698","article-title":"191Pt-labeled agents targeting DNA: compound design and biological evaluation for targeted Auger electron therapy [abstract]","volume":"64(suppl 1)","author":"Obata","year":"2023","journal-title":"J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.129","doi-asserted-by":"crossref","first-page":"109043","DOI":"10.1016\/j.nucmedbio.2025.109043","article-title":"Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in\u00a0vivo properties","volume":"146\u2013147","author":"Obata","year":"2025","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.apradiso.2019.04.007","article-title":"Production of 191Pt from an iridium target by vertical beam irradiation and simultaneous alkali fusion","volume":"149","author":"Obata","year":"2019","journal-title":"Appl Radiat Isot."},{"key":"2026091111400909000_67.Supplement_2.5S.131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.03.012","article-title":"Targeted Auger electron-emitter therapy: radiochemical approaches for thallium-201 radiopharmaceuticals","volume":"98\u201399","author":"Rigby","year":"2021","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-021-00802-w","article-title":"In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201","volume":"11","author":"Osytek","year":"2021","journal-title":"EJNMMI Res."},{"key":"2026091111400909000_67.Supplement_2.5S.133","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1021\/acs.bioconjchem.2c00284","article-title":"Toward bifunctional chelators for thallium-201 for use in nuclear medicine","volume":"33","author":"Rigby","year":"2022","journal-title":"Bioconjug Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.134","doi-asserted-by":"crossref","first-page":"111128","DOI":"10.1016\/j.apradiso.2023.111128","article-title":"Production of pharmaceutical grade [201Tl]thallous chloride using 30 MeV cyclotron","volume":"204","author":"Chattopadhyay","year":"2024","journal-title":"Appl Radiat Isot."},{"key":"2026091111400909000_67.Supplement_2.5S.135","doi-asserted-by":"crossref","unstructured":"Del Olmo-Garc\u00eda MI Prado-Wohlwend S Bello P Segura A Merino-Torres JF . Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in patients with advanced GEP NENS: present and future directions. Cancers (Basel). 2022;14:584.","DOI":"10.3390\/cancers14030584"},{"key":"2026091111400909000_67.Supplement_2.5S.136","doi-asserted-by":"crossref","first-page":"A707","DOI":"10.1007\/s10582-003-0090-z","article-title":"Radioisotope radiotherapy research and achievements at the University of Missouri Research Reactor","volume":"53","author":"Ehrhardt","year":"2003","journal-title":"Czech J Phys."},{"key":"2026091111400909000_67.Supplement_2.5S.137","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/18744729MTEwCMjkE0","article-title":"IAEA activities on 67Cu, 186Re, 47Sc theranostic radionuclides and radiopharmaceuticals","volume":"14","author":"Jalilian","year":"2021","journal-title":"Curr Radiopharm."},{"key":"2026091111400909000_67.Supplement_2.5S.138","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13139-018-0523-z","article-title":"Current Consensus on I-131 MIBG therapy","volume":"52","author":"Kayano","year":"2018","journal-title":"Nucl Med Mol Imaging."},{"key":"2026091111400909000_67.Supplement_2.5S.139","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41181-025-00344-9","article-title":"[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production","volume":"10","author":"Aurilio","year":"2025","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.140","doi-asserted-by":"crossref","first-page":"108975","DOI":"10.1016\/j.nucmedbio.2024.108975","article-title":"225A\u0441\/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates","volume":"140\u2013141","author":"Ermolaev","year":"2025","journal-title":"Nucl Med Biol."},{"key":"2026091111400909000_67.Supplement_2.5S.141","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1292"},{"key":"2026091111400909000_67.Supplement_2.5S.142","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2013.01.010"},{"key":"2026091111400909000_67.Supplement_2.5S.143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41181-021-00121-4","article-title":"Production, purification, and radiolabeling of the 203Pb\/212Pb theranostic pair","volume":"6","author":"McNeil","year":"2021","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.144","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2427-6"},{"key":"2026091111400909000_67.Supplement_2.5S.145","first-page":"77","article-title":"Almost a designer radioiodine for thyroid scanning","volume":"43","author":"Park","year":"2002","journal-title":"J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.146","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/1450-1147.163259","article-title":"Indium-111 capromab pendetide (ProstaScint\u00ae) demonstrates renal cell carcinoma and aortocaval nodal metastases from prostate adenocarcinoma","volume":"14","author":"Rizvi","year":"2015","journal-title":"World J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.147","first-page":"282","article-title":"Gallium: mechanisms","volume":"21","author":"Hoffer","year":"1980","journal-title":"J Nucl Med."},{"key":"2026091111400909000_67.Supplement_2.5S.148","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10967-018-6284-4","article-title":"201Tl production through light charged-particle induced reactions on Tl and Hg isotopes: theoretical and simulation approaches","volume":"319","author":"Nikjou","year":"2019","journal-title":"J Radioanal Nucl Chem."},{"key":"2026091111400909000_67.Supplement_2.5S.149","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.apradiso.2011.05.016","article-title":"Production and separation of no-carrier-added thallium isotopes from proton irradiated natHg2Cl2 matrix","volume":"69","author":"Dutta","year":"2011","journal-title":"Appl Radiat Isot."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:41:07Z","timestamp":1789152067000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":149,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.125.269487"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269487","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}